Send us Feedback

ISTA Pharmaceuticals (ISTA)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ISTA » Topics » Signatures

This excerpt taken from the ISTA 8-K filed Dec 17, 2009.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
December 17, 2009     By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer and Vice President, Corporate Development

This excerpt taken from the ISTA 8-K filed Nov 3, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ISTA PHARMACEUTICALS, INC.
November 3, 2009   By:   /S/    LAUREN P. SILVERNAIL      
    Lauren P. Silvernail
   

Chief Financial Officer and Vice

President, Corporate Development

This excerpt taken from the ISTA 8-K filed Aug 26, 2009.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
August 26, 2009     By:   /s/ Lauren P. Silvernail
      Lauren P. Silvernail
     

Chief Financial Officer and Vice President,

Corporate Development

This excerpt taken from the ISTA 8-K filed Aug 5, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ISTA PHARMACEUTICALS, INC.

August 5, 2009

   By:  

/s/ Lauren P. Silvernail

    Lauren P. Silvernail
   

Chief Financial Officer and Vice

President, Corporate Development

This excerpt taken from the ISTA 10-Q filed May 12, 2009.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, ISTA Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

ISTA PHARMACEUTICALS, INC.

(Registrant)

Dated: May 12, 2009     /s/ Vicente Anido, Jr., Ph.D.
    Vicente Anido, Jr., Ph.D.
    President and Chief Executive Officer
Dated: May 12, 2009     /s/ Lauren P. Silvernail
    Lauren P. Silvernail
   

Chief Financial Officer and

Vice President, Corporate Development

 

21

Table of Contents
This excerpt taken from the ISTA 8-K filed May 7, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
May 7, 2009     By:  

/s/ Lauren P. Silvernail

     

Lauren P. Silvernail

     

Chief Financial Officer and Vice

President, Corporate Development

These excerpts taken from the ISTA 10-K filed Apr 28, 2009.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on April 28, 2009.

 

By:  

/s/    Vicente Anido, Jr., Ph.D.

  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

 

27

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on April 28, 2009.

 

By:  

/s/    Vicente Anido, Jr., Ph.D.

  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

 

27

Table of Contents

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on
April 28, 2009.

 




















By: 

/s/    Vicente Anido, Jr., Ph.D.

 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer

 


27






Table of Contents


SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on
April 28, 2009.

 




















By: 

/s/    Vicente Anido, Jr., Ph.D.

 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer

 


27






Table of Contents


This excerpt taken from the ISTA 8-K filed Mar 6, 2009.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
March 6, 2009     By:   /s/ Lauren P. Silvernail
       

Lauren P. Silvernail

Chief Financial Officer, Chief Accounting Officer & Vice President, Corporate Development

This excerpt taken from the ISTA 8-K filed Feb 26, 2009.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
February 26, 2009     By:   /s/ Lauren P. Silvernail
      Lauren P. Silvernail
      Chief Financial Officer, Chief Accounting Officer & Vice President, Corporate Development

These excerpts taken from the ISTA 10-K filed Feb 23, 2009.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 23, 2009.

 

By:  

/S/ VICENTE ANIDO, JR., PH.D.

  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 23, 2009.

 

By:  

/S/ VICENTE ANIDO, JR., PH.D.

  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 23, 2009.

 

By:  

/S/ VICENTE ANIDO, JR., PH.D.

  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 23, 2009.

STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> 




















By: 

/S/ VICENTE ANIDO, JR.,
PH.D.

 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 23, 2009.

STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> 




















By: 

/S/ VICENTE ANIDO, JR.,
PH.D.

 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 23, 2009.

STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> 




















By: 

/S/ VICENTE ANIDO, JR.,
PH.D.

 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer
This excerpt taken from the ISTA 8-K filed Feb 19, 2009.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
February 19, 2009     By:   /s/ Lauren P. Silvernail
     

Lauren P. Silvernail

Chief Financial Officer, Chief Accounting

Officer & Vice President, Corporate

Development

This excerpt taken from the ISTA 8-K filed Feb 10, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
February 10, 2009     By:   /s/ Lauren P. Silvernail
       

Lauren P. Silvernail

Chief Financial Officer, Chief Accounting

Officer & Vice President, Corporate Development

This excerpt taken from the ISTA 8-K filed Feb 9, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
February 9, 2009     By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer, Chief Accounting
        Officer & Vice President, Corporate Development
This excerpt taken from the ISTA 8-K filed Dec 24, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ISTA PHARMACEUTICALS, INC.
December 24, 2008   By:  

/s/    Lauren P. Silvernail

    Lauren P. Silvernail
   

Chief Financial Officer, Chief Accounting Officer and

Vice President, Corporate Development

This excerpt taken from the ISTA 8-K filed Nov 3, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
November 3, 2008     By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer, Chief Accounting Officer and Vice President, Corporate Development
This excerpt taken from the ISTA 10-Q filed Oct 31, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, ISTA Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

ISTA PHARMACEUTICALS, INC.

(Registrant)

Dated: October 31, 2008     /s/ Vicente Anido, Jr., Ph.D.
    Vicente Anido, Jr., Ph.D.
    President and Chief Executive Officer
Dated: October 31, 2008     /s/ Lauren P. Silvernail
    Lauren P. Silvernail
   

Chief Financial Officer and

Vice President, Corporate Development

 

24

Table of Contents
This excerpt taken from the ISTA 8-K filed Oct 30, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
October 30, 2008     By:  

/s/ Lauren P. Silvernail

     

Lauren P. Silvernail

     

Chief Financial Officer and Vice

President, Corporate Development

This excerpt taken from the ISTA 8-K filed Sep 30, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
September 30, 2008     By:   /s/ Lauren P. Silvernail
      Lauren P. Silvernail
     

Chief Financial Officer, Chief Accounting Officer

and Vice President, Corporate Development

 

This excerpt taken from the ISTA 10-Q filed Aug 8, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, ISTA Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

ISTA PHARMACEUTICALS, INC.

(Registrant)

Dated: August 8, 2008     /s/ Vicente Anido, Jr., Ph.D.
    Vicente Anido, Jr., Ph.D.
    President and Chief Executive Officer
Dated: August 8, 2008     /s/ Lauren P. Silvernail
    Lauren P. Silvernail
   

Chief Financial Officer and

Vice President, Corporate Development

 

22

Table of Contents
This excerpt taken from the ISTA 8-K filed Aug 7, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
  August 7, 2008     By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer and Vice President, Corporate Development

This excerpt taken from the ISTA 8-K filed Jul 3, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
July 3, 2008     By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer,
Chief Accounting Officer and Vice President,
Corporate Development

This excerpt taken from the ISTA 10-Q filed May 1, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, ISTA Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

ISTA PHARMACEUTICALS, INC.

(Registrant)

Dated: May 1, 2008     /s/ Vicente Anido, Jr., Ph.D.
    Vicente Anido, Jr., Ph.D.
    President and Chief Executive Officer
Dated: May 1, 2008     /s/ Lauren P. Silvernail
    Lauren P. Silvernail
   

Chief Financial Officer and

Vice President, Corporate Development

 

19

Table of Contents
This excerpt taken from the ISTA 8-K filed Apr 30, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
April 30, 2008     By:   /s/ Lauren P. Silvernail
       

Lauren P. Silvernail

Chief Financial Officer and Vice

President, Corporate Development

These excerpts taken from the ISTA 10-K filed Apr 28, 2008.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on April 28, 2008.

 

By:   /s/ Vicente Anido, Jr., Ph.D.
  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

 

34

Table of Contents

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on
April 28, 2008.

 























By: /s/ Vicente Anido, Jr., Ph.D.
 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer

 


34






Table of Contents


This excerpt taken from the ISTA 8-K filed Apr 10, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
April 10, 2008     By:   /s/ Lauren P. Silvernail
       

Lauren P. Silvernail

Chief Financial Officer, Chief Accounting

Officer and Vice President, Corporate Development

 

This excerpt taken from the ISTA 8-K filed Mar 31, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
March 31, 2008     By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer, Chief Accounting Officer and Vice President, Corporate Development

These excerpts taken from the ISTA 10-K filed Mar 7, 2008.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on March 3, 2008.

 

By:   /s/ VICENTE ANIDO, JR., PH.D.
  Vicente Anido, Jr., Ph.D.
  President and Chief Executive Officer

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form 10-K and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on March 3, 2008.

STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> 























By: /s/ VICENTE ANIDO, JR., PH.D.
 Vicente Anido, Jr., Ph.D.
 President and Chief Executive Officer
This excerpt taken from the ISTA 8-K filed Mar 6, 2008.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
March 6, 2008     By:   /s/ Lauren P. Silvernail
       

Lauren P. Silvernail

Chief Financial Officer, Chief Accounting

Officer & Vice President, Corporate Development

This excerpt taken from the ISTA 8-K filed Feb 13, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
February 13, 2008    
      By:   /s/ Lauren P. Silvernail
        Lauren P. Silvernail
        Chief Financial Officer, Chief Accounting
        Officer & Vice President, Corporate Development
This excerpt taken from the ISTA 10-Q filed Nov 6, 2007.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, ISTA Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    ISTA PHARMACEUTICALS, INC.
    (Registrant)
Dated: November 6, 2007       /s/ Vicente Anido, Jr., Ph.D.
      Vicente Anido, Jr., Ph.D.
      President and Chief Executive Officer

 

Dated: November 6, 2007       /s/ Lauren P. Silvernail
      Lauren P. Silvernail
      Chief Financial Officer,
      Chief Accounting Officer and
      Vice President, Corporate Development

 

17

Table of Contents

EXCERPTS ON THIS PAGE:

8-K
Dec 17, 2009
8-K
Nov 3, 2009
8-K
Aug 26, 2009
8-K
Aug 5, 2009
10-Q
May 12, 2009
8-K
May 7, 2009
10-K (4 sections)
Apr 28, 2009
8-K
Mar 6, 2009
8-K
Feb 26, 2009
10-K (6 sections)
Feb 23, 2009
8-K
Feb 19, 2009
8-K
Feb 10, 2009
8-K
Feb 9, 2009
8-K
Dec 24, 2008
8-K
Nov 3, 2008
10-Q
Oct 31, 2008
8-K
Oct 30, 2008
8-K
Sep 30, 2008
10-Q
Aug 8, 2008
8-K
Aug 7, 2008
8-K
Jul 3, 2008
10-Q
May 1, 2008
8-K
Apr 30, 2008
10-K (2 sections)
Apr 28, 2008
8-K
Apr 10, 2008
8-K
Mar 31, 2008
10-K (2 sections)
Mar 7, 2008
8-K
Mar 6, 2008
8-K
Feb 13, 2008
10-Q
Nov 6, 2007

RELATED TOPICS for ISTA:

"Signatures" elsewhere:

Pfizer (PFE)
ABAXIS (ABAX)
ABIOMED (ABMD)
Akorn (AKRX)
AMAG Pharmaceuticals (AMAG)
BMP Sunstone CORP (BJGP)
Immucor (BLUD)
Chindex International (CHDX)
China Medical Technologies (CMED)
Conceptus (CPTS)
CryoLife (CRY)
Cynosure (CYNO)
EpiCept (EPCT)
EResearch Technology (ERES)
Given Imaging (GIVN)
Genelabs Technologies (GNLB)
Human Genome Sciences (HGSI)
Hooper Holmes (HH)
ImmuCell (ICCC)
Icagen (ICGN)
IDEXX Laboratories (IDXX)
Immunomedics (IMMU)
Infinity Pharmaceuticals (INFI)
Inspire Pharmaceuticals (ISPH)
Lannett Co (LCI)
MedCath (MDTH)
Monogram Biosciences (MGRM)
Mannatech (MTEX)
Myriad Genetics (MYGN)
National Dentex (NADX)
Neogen (NEOG)
NightHawk Radiology Holdings (NHWK)
NovaMed (NOVA)
NPS Pharmaceuticals (NPSP)
Nymox Pharmaceutical (NYMX)
Orchid Cellmark (ORCH)
Quidel (QDEL)
RTI Biologics, Inc. (RTIX)
SciClone Pharmaceuticals (SCLN)
Shamir Optical Industry (SHMR)
Spectranetics (SPNC)
SurModics (SRDX)
Threshold Pharmaceuticals (THLD)
Raptor Pharmaceutical Corp (TPTX)
Meridian Bioscience (VIVO)
ZymoGenetics (ZGEN)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki